Targeting dendritic cells: a promising strategy to improve vaccine effectiveness

Dendritic cell (DC) targeting is a novel strategy to enhance vaccination efficacy. This approach is based on the in situ delivery of antigen via antibodies that are specific for endocytic receptors expressed at the surface of DCs. Here we review the complexity of the DC subsets and the antigen presentation pathways that need to be considered in the settings of DC targeting. We also summarize current knowledge about antigen delivery to DCs via DEC‐205, Clec9A and Clec12A, receptor targets that strongly enhance cellular and humoral immune responses. Finally, we discuss the intracellular trafficking criteria of the targeted receptors that may impact their effectiveness as DC targets.

• Publication year

  2016

• Venue

  Clinical & Translational Immunology

• Publication date

  2016-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/cti.2016.6PMID 27217957PMCID 4815026
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting Antigen to Clec9A Primes Follicular Th Cell Memory Responses Capable of Robust Recall

  2015cited by this paper
• Criteria for Dendritic Cell Receptor Selection for Efficient Antibody-Targeted Vaccination

  2015cited by this paper
• The multifaceted biology of plasmacytoid dendritic cells

  2015cited by this paper
• Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non‐human primates

  2015cited by this paper
• The ins and outs of MHC class II-mediated antigen processing and presentation

  2015cited by this paper
• Enhanced Humoral Responses Induced by Targeting of Antigen to Murine Dendritic Cells

  2015cited by this paper
• T Cells To Produce Type 2 Cytokines + Dendritic Cells Induce CD4 + Human CD141

  2014cited by this paper
• Human Dermal CD14+ Cells Are a Transient Population of Monocyte-Derived Macrophages

  2014cited by this paper
• Human CD141+ Dendritic Cells Induce CD4+ T Cells To Produce Type 2 Cytokines

  2014cited by this paper
• Regulation of the tolerogenic function of steady‐state DCs

  2014cited by this paper
• Human inflammatory dendritic cells induce Th17 cell differentiation.

  2013cited by this paper
• IRF4 Transcription Factor-Dependent CD11b+ Dendritic Cells in Human and Mouse Control Mucosal IL-17 Cytokine Responses

  2013cited by this paper
• Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ–resident dendritic cells

  2013cited by this paper
• Evolution of B Cell Responses to Clec9A-Targeted Antigen

  2013cited by this paper
• Pathways of antigen processing.

  2013cited by this paper
• Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation

  2013cited by this paper
• Targeting antigen to bone marrow stromal cell‐2 expressed by conventional and plasmacytoid dendritic cells elicits efficient antigen presentation

  2013cited by this paper
• DEC-205 is a cell surface receptor for CpG oligonucleotides

  2013cited by this paper
• Inflammatory dendritic cells in mice and humans.

  2013cited by this paper
• Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells.

  2012cited by this paper
• DEC-205 is a cell surface receptor for CpG oligonucleotides

  2012cited by this paper
• Skin Langerin+ Dendritic Cells Transport Intradermally Injected Anti–DEC-205 Antibodies but Are Not Essential for Subsequent Cytotoxic CD8+ T Cell Responses

  2012cited by this paper
• The differential production of cytokines by human Langerhans cells and dermal CD14(+) DCs controls CTL priming.

  2012cited by this paper
• DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues.

  2012cited by this paper
• Characterization of resident and migratory dendritic cells in human lymph nodes

  2012cited by this paper
• The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments.

  2012cited by this paper
• Boosting antibody responses by targeting antigens to dendritic cells.

  2012cited by this paper
• F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells.

  2012cited by this paper
• Skin-resident murine dendritic cell subsets promote distinct and opposing antigen-specific T helper cell responses.

  2011cited by this paper
• Human Langerhans cells capture measles virus through Langerin and present viral antigens to CD4+ T cells but are incapable of cross‐presentation

  2011cited by this paper
• Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation.

  2011cited by this paper
• Targeting Antigen to Mouse Dendritic Cells via Clec9A Induces Potent CD4 T Cell Responses Biased toward a Follicular Helper Phenotype

  2011cited by this paper
• Sec22b regulates phagosomal maturation and antigen crosspresentation by dendritic cells.

  2011cited by this paper
• Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A

  2011cited by this paper
• Antibody-Targeted NY-ESO-1 to Mannose Receptor or DEC-205 In Vitro Elicits Dual Human CD8+ and CD4+ T Cell Responses with Broad Antigen Specificity

  2011cited by this paper
• DEC‐205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells

  2011cited by this paper
• Heat shock protein 90 (HSP90) contributes to cytosolic translocation of extracellular antigen for cross-presentation by dendritic cells

  2011cited by this paper
• Towards a systems understanding of MHC class I and MHC class II antigen presentation

  2011cited by this paper
• Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation.

  2010cited by this paper
• Epidermal Langerhans cells rapidly capture and present antigens from C-type lectin-targeting antibodies deposited in the dermis.

  2010cited by this paper
• Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells

  2010cited by this paper
• Defective Cross-Presentation of Viral Antigens in GILT-Free Mice

  2010cited by this paper
• Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1/CLEC9A

  2010cited by this paper
• Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8+ T cell responses to influenza

  2010cited by this paper
• Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8α+ dendritic cells

  2010cited by this paper
• Different cross-presentation pathways in steady-state and inflammatory dendritic cells

  2009cited by this paper
• Identification of a dendritic cell receptor that couples sensing of necrosis to immunity

  2009cited by this paper
• The small GTPase Rac2 controls phagosomal alkalinization and antigen crosspresentation selectively in CD8(+) dendritic cells.

  2009cited by this paper
• CD205 (DEC-205): A recognition receptor for apoptotic and necrotic self

  2009cited by this paper
• Skin Inflammation Is Not Sufficient to Break Tolerance Induced against a Novel Antigen1

  2009cited by this paper
• Langerhans Cells Are Not Required for the CD8 T Cell Response to Epidermal Self-Antigens 1

  2009cited by this paper
• Blood-derived inflammatory dendritic cells in lymph nodes stimulate acute TH1 immune responses

  2009cited by this paper
• Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation

  2009cited by this paper
• The C-Type Lectin Clec12A Present on Mouse and Human Dendritic Cells Can Serve as a Target for Antigen Delivery and Enhancement of Antibody Responses1

  2009cited by this paper
• Antigen presentation by dendritic cells in vivo.

  2009cited by this paper
• NADPH oxidase controls phagosomal pH and antigen cross-presentation in human dendritic cells.

  2008cited by this paper
• Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells

  2008cited by this paper
• Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells

  2008cited by this paper
• The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement.

  2008cited by this paper
• CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses

  2008cited by this paper
• Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin.

  2008cited by this paper
• Plasmacytoid dendritic cells mediate oral tolerance.

  2008cited by this paper
• Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells.

  2008cited by this paper
• Altered expression and endocytic function of CD205 in human dendritic cells, and detection of a CD205–DCL‐1 fusion protein upon dendritic cell maturation

  2007cited by this paper
• Steady-state and inflammatory dendritic-cell development

  2007cited by this paper
• Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

  2007cited by this paper
• Differential Antigen Processing by Dendritic Cell Subsets in Vivo

  2007cited by this paper
• DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes

  2007cited by this paper
• Hsp90-mediated cytosolic refolding of exogenous proteins internalized by dendritic cells

  2007cited by this paper
• Expression of human DEC-205 (CD205) multilectin receptor on leukocytes.

  2006cited by this paper
• NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells.

  2006cited by this paper
• Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis

  2006cited by this paper
• Langerhans cells cross-present antigen derived from skin

  2006cited by this paper
• A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells.

  2006cited by this paper
• Control of MHC class II antigen presentation in dendritic cells: a balance between creative and destructive forces

  2005cited by this paper
• CD4 T Cell Responses Elicited by Different Subsets of Human Skin Migratory Dendritic Cells

  2005cited by this paper
• Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo

  2005cited by this paper
• CD4+ T Cell Responses Elicited by Different Subsets of Human Skin Migratory Dendritic Cells1

  2005cited by this paper
• Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice.

  2005cited by this paper
• Essential Role of Lung Plasmacytoid Dendritic Cells in Preventing Asthmatic Reactions to Harmless Inhaled Antigen

  2004cited by this paper
• In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination

  2004cited by this paper
• ER–phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells

  2003cited by this paper
• Phagosomes are competent organelles for antigen cross-presentation

  2003cited by this paper
• Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells.

  2003cited by this paper
• Activation of Lysosomal Function During Dendritic Cell Maturation

  2003cited by this paper
• Antigen Presentation by Dendritic Cells In Vivo

  2002cited by this paper
• Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance

  2002cited by this paper
• Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo

  2001cited by this paper
• Capture and processing of exogenous antigens for presentation on MHC molecules.

  1997cited by this paper
• Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. I. Expression on dendritic cells and other subsets of mouse leukocytes.

  1995cited by this paper
• Pathways of antigen processing.

  1991cited by this paper

• Protein-Capturing Microgel-Integrated Microneedle Array Patches for Enhanced Tip-Loading, Storage Stability, and Transdermal Delivery of Recombinant Proteins.

  2026cites this paper
• Dendritic cell-based vaccines, a promising prospect for ending AIDS and eradication of HIV worldwide: A narrative review on the latest updates.

  2025cites this paper
• Prior appendectomy attenuates the immune protective efficacy of BCG vaccination against Mycobacterium tuberculosis infection.

  2025cites this paper
• iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA

  2025cites this paper
• Dendritic Cell Therapy in Chronic Viral Infections: Current Applications, Challenges, and Future Perspectives

  2025cites this paper
• A review of vaccinology and ex vivo antigen-loaded dendritic cells: A different approach to infectious disease vaccines

  2025cites this paper
• Dendritic Cell Immunotherapy for Solid Tumors: Advances in Translational Research and Clinical Application

  2025cites this paper
• Immature dendritic cell-targeting mRNA vaccine expressing PfCSP enhances protective immune responses against Plasmodium liver infection

  2024cites this paper
• Single-shot dendritic cell targeting SARS-CoV-2 vaccine candidate induces broad, durable and protective systemic and mucosal immunity in mice

  2024cites this paper
• FcRn regulates antigen presentation in dendritic cells downstream of DEC205-targeted vaccines

  2024cites this paper
• Circular RNA vaccines: Pioneering the next-gen cancer immunotherapy

  2024cites this paper
• Current Strategies for the Development of a Therapeutic Cancer Vaccine – A Review

  2024cites this paper
• Personalized cancer vaccine design using AI-powered technologies

  2024cites this paper
• Recent Review on Biological Barriers and Host–Material Interfaces in Precision Drug Delivery: Advancement in Biomaterial Engineering for Better Treatment Therapies

  2024cites this paper
• Intestinal Lymphatic Biology, Drug Delivery, and Therapeutics: Current Status and Future Directions

  2024cites this paper
• Bacterial membrane vesicles combined with nanoparticles for bacterial vaccines and cancer immunotherapy.

  2024cites this paper
• Crosstalking with dendritic cells: a path to engineer advanced T Cell immunotherapy

  2024cites this paper
• Enhancing cell-mediated immunity through dendritic cell activation: the role of Tri-GalNAc-modified PLGA-PEG nanoparticles encapsulating SR717

  2024cites this paper
• Dendritic cell targeting peptide plus Salmonella FliCd flagellin fused outer membrane protein H (OmpH) demonstrated increased efficacy against infections caused by different Pasteurella multocida serogroups in mouse models.

  2024cites this paper
• Therapeutic proteins: developments, progress, challenges, and future perspectives

  2024cites this paper
• Dendritic cell targeting SMART-lipid nanoparticles enabled mRNA vaccine elicits cross-reactive humoral responses against the omicron sub-variants.

  2024cites this paper
• Immunoprotection of FliBc chimeric fiber2 fusion proteins targeting dendritic cells against Fowl adenovirus serotype 4 infection

  2024cites this paper
• The XCL1-Mediated DNA Vaccine Targeting Type 1 Conventional Dendritic Cells Combined with Gemcitabine and Anti-PD1 Antibody Induces Potent Antitumor Immunity in a Mouse Lung Cancer Model

  2024cites this paper
• Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines

  2023cites this paper
• Immunodominant conserved moieties on spike protein of SARS-CoV-2 renders virulence factor for the design of epitope-based peptide vaccines

  2023cites this paper
• Messenger RNA vaccines and their delivery strategies: A journey from infectious diseases to cancer.

  2023cites this paper
• Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment

  2023cites this paper
• On the Path to Predicting Immune Responses in the Lung: Modeling the Pulmonary Innate Immune system at the Air-Liquid Interface (ALI).

  2023cites this paper
• Recombinant antigen delivery to dendritic cells as a way to improve vaccine design

  2023cites this paper
• Enhanced Vaccine Immunogenicity Enabled by Targeted Cytosolic Delivery of Tumor Antigens into Dendritic Cells

  2023cites this paper
• Chicken dendritic cell-targeting nanobodies mediated improved protective effects against H9N2 influenza virus challenge in a homologous sequential immunization study.

  2023cites this paper
• Metabolic glycan labeling immobilizes dendritic cell membrane and enhances antitumor efficacy of dendritic cell vaccine

  2023cites this paper
• Improving the efficacy of peptide vaccines in cancer immunotherapy.

  2023cites this paper
• Lymph node targeting for immunotherapy

  2023cites this paper
• Vaccine delivery by zwitterionic polysaccharide-based hydrogel microparticles showing enhanced immunogenicity and suppressed foreign body responses.

  2023cites this paper
• Application of Nano-Delivery Systems in Lymph Nodes for Tumor Immunotherapy

  2023cites this paper
• Advanced liposome and polymersome-based drug delivery systems: Considerations for physicochemical properties, targeting strategies and stimuli-sensitive approaches.

  2023cites this paper
• Targeting dendritic cells to advance cross-presentation and vaccination outcomes.

  2023cites this paper
• Promoting immunity with novel targeting antigen delivery vehicle based on bispecific nanobody.

  2023cites this paper
• SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines

  2023cites this paper
• “Just right” combinations of adjuvants with nanoscale carriers activate aged dendritic cells without overt inflammation

  2023cites this paper
• Mycobacterium avium subsp. paratuberculosis antigens induce cellular immune responses in cattle without causing reactivity to tuberculin in the tuberculosis skin test

  2023cites this paper
• New Approaches to Dendritic Cell-Based Therapeutic Vaccines Against HIV-1 Infection

  2022cites this paper
• Synthesis & Evaluation of Novel Mannosylated Neoglycolipids for Liposomal Delivery System Applications

  2022cites this paper
• Efficient antigen delivery by dendritic cell-targeting peptide via nucleolin confers superior vaccine effects in mice

  2022cites this paper
• A lentiviral vector expressing a dendritic cell-targeting multimer induces mucosal anti-mycobacterial CD4+ T-cell immunity

  2022cites this paper
• Delivery of antigen to porcine dendritic cells by fusing antigen with porcine dendritic cells targeting peptide

  2022cites this paper
• Stem-like T cells and niches: Implications in human health and disease

  2022cites this paper
• Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities

  2022cites this paper
• Emerging applications of nanobodies in cancer therapy.

  2022cites this paper
• Splenic Dendritic Cells and Macrophages Drive B Cells to Adopt a Plasmablast Cell Fate

  2022cites this paper
• Dendritic Cells - Win the Fight Against HIV.

  2022cites this paper
• Combined effects of oncolytic vaccinia virus and dendritic cells on the progression of melanoma B16-F10 in mice

  2022cites this paper
• Physical and chemical advances of synthetic delivery vehicles to enhance mRNA vaccine efficacy.

  2022cites this paper
• Applications of Antibody-Based Antigen Delivery Targeted to Dendritic Cells In Vivo

  2022cites this paper
• Delivery strategies for cancer vaccines and immunoadjuvants

  2022cites this paper
• ADP-ribosylating adjuvant reveals plasticity in cDC1 cells that drive mucosal Th17 cell development and protection against influenza virus infection

  2021cites this paper
• Pulmonary delivery of mucosal nanovaccines

  2021cites this paper
• Mechanisms underpinning poor antibody responses to vaccines in ageing

  2021cites this paper
• Robust Antigen-Specific T Cell Activation within Injectable 3D Synthetic Nanovaccine Depots

  2021cites this paper
• Fantastic Voyage 2021: Using Interactive VR Storytelling to Explain Targeted COVID-19 Vaccine Delivery to Antigen-presenting Cells

  2021cites this paper
• Advancing Adjuvants for Mycobacterium tuberculosis Therapeutics

  2021cites this paper
• Pattern recognition receptor expression and maturation profile of dendritic cell subtypes in human tonsils and lymph nodes.

  2021cites this paper
• Progress in the Application of Drugs for the Treatment of Multiple Sclerosis

  2021cites this paper
• A bird's eye view on the role of dendritic cells in SARS‐CoV‐2 infection: Perspectives for immune‐based vaccines

  2021cites this paper
• Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines

  2021cites this paper
• Preclinical models and technologies to advance nanovaccine development.

  2021cites this paper
• Therapeutic dendritic cell cancer vaccines in hematologic malignancies

  2021cites this paper
• New Therapies for Melanoma Cancer Strategies

  2021influential citation
• Complement-Opsonized Nano-Carriers Are Bound by Dendritic Cells (DC) via Complement Receptor (CR)3, and by B Cell Subpopulations via CR-1/2, and Affect the Activation of DC and B-1 Cells

  2021cites this paper
• Opportunities for innovation: Building on the success of lipid nanoparticle vaccines

  2021cites this paper
• Induction of Therapeutic Protection in an HPV16-Associated Mouse Tumor Model Through Targeting the Human Papillomavirus-16 E5 Protein to Dendritic Cells

  2021cites this paper
• Conversations that count: Cellular interactions that drive T cell fate

  2021cites this paper
• An overview of chitosan and its application in infectious diseases

  2021cites this paper
• The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies?

  2021cites this paper
• Evaluation of transduced dendritic cells expressing HIV-1 p24-Nef antigens in HIV-specific cytotoxic T cells induction as a therapeutic candidate vaccine.

  2021cites this paper
• Immunomodulatory Dual-Sized Microparticle System Conditions Human Antigen Presenting Cells Into a Tolerogenic Phenotype In Vitro and Inhibits Type 1 Diabetes-Specific Autoreactive T Cell Responses

  2020cites this paper
• Mucosal vaccines: Strategies and challenges.

  2020cites this paper
• Selective uptake of chitosan polymeric micelles by circulating monocytes for enhanced tumor targeting.

  2020cites this paper
• Ex vivo assessment of in vivo DC-targeted antibodies in pre-clinical models.

  2020cites this paper
• Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.

  2020cites this paper
• Dendritic Cells and Their Roles in Anti-Tumour Immunity

  2020cites this paper
• Preclinical Efficacy of a Trivalent Human FcγRI-Targeted Adjuvant-Free Subunit Mucosal Vaccine against Pulmonary Pneumococcal Infection

  2020cites this paper
• Characterization of the Porcine CLEC12A and Analysis of Its Expression on Blood Dendritic Cell Subsets

  2020cites this paper
• Precisely targeted gene delivery in human skin using supramolecular cationic glycopolymers

  2020cites this paper
• Porcine CLEC12B is expressed on alveolar macrophages and blood dendritic cells.

  2020cites this paper
• Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy

  2020cites this paper
• Modulation of immune responses using adjuvants to facilitate therapeutic vaccination

  2020cites this paper
• Nucleic Acid-Based Approaches for Tumor Therapy

  2020cites this paper
• Engineering precision nanoparticles for drug delivery

  2020cites this paper
• Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets

  2020cites this paper
• Self-assembled particulate vaccine elicits strong immune responses and reduces Mycobacterium avium subsp. paratuberculosis infection in mice

  2020cites this paper
• Chemo-physical Strategies to Advance the in Vivo Functionality of Targeted Nanomedicine: The Next Generation.

  2020cites this paper
• The applications of anti-CD20 antibodies to treat various B cells disorders.

  2019cites this paper
• The Way Forward: Potentiating Protective Immunity to Novel and Pandemic Influenza Through Engagement of Memory CD4 T Cells

  2019cites this paper
• Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity

  2019cites this paper
• Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy

  2019cites this paper
• Nanoparticles: Properties and Applications in Cancer Immunotherapy.

  2019cites this paper
• Simultaneous delivery of DNA vaccine and hydrophobic adjuvant using reducible polyethylenimine-functionalized graphene oxide for activation of dendritic cells

  2019cites this paper
• Conjugation of an scFab domain to the oligomeric HIV envelope protein for use in immune targeting

  2019cites this paper